

AHMEDABAD
21.4.2005

PRESS RELEASE

-
- 1. HESTER PHARMA registers a growth of 269% in Net Profit and 111% in Sales over last year,**
 - 2. Has recommended a 12% dividend for the year 2004-2005,**
 - 3. Embarks on an expansion plan.**
-

Hester is a leading biotech company in the field of veterinary biologicals, producing poultry vaccine in Ahmedabad, India.

Hester's Profit Before Tax for the year ended 31.3.2005 is recorded at Rs. 6.35 crores as compared to Rs. 1.95 crores for the year ended 31.3.2004, registering a growth of 226%.

The company's turnover of Rs. 16.24 crores for the year ended 31.3.2005 compared to a turnover of Rs. 7.68 crores for the year ended 31.3.2004, thereby registering an increase of 111%.

As compared to the financial year ended 31.3.2004, Profit After Tax is higher by 269% and Earnings Per Share is at Rs. 11.18 as on 31.3.2005 (Rs. 3.03 as on 31.3.2004).

The board of directors has recommended a dividend for the financial year 2004-2005 of Rs. 1.20 per equity share of Rs. 10.00 each (12%), subject to the approval at the ensuing AGM.

Considering the growth of the poultry industry in India and the over whelming demand for it's range of poultry vaccines, Hester has on hand an expansion plan for increasing it's current capacity by 300% which would go on-stream in the last quarter of the current financial year. This expansion envisages adding new product lines of poultry vaccines and other large animal vaccines.

Rajiv Gandhi
Managing Director
Hester Pharmaceuticals Limited
www.hesterpharma.co.in
rajiv@hesterpharma.co.in